A Phase 4 interventional study of Single, weight-adjusted i.v. bolus of tenecteplase and catheterisation in STEMI - ST Elevation Myocardial Infarction, sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation. Not yet recruiting at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims at evaluating of the effectiveness of in-hospital thrombolysis for ST-segment elevation myocardial infarction in PCI centers under conditions of predicted in-hospital delay (>60 min after admission in PCI-center) of PCI. Following randomisation a strategy of early tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 2-24 hours with timely coronary intervention as appropriate (or by rescue coronary intervention if required) in Group A will be compared to primary PCI performed according to local standards in Group B.
855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.
This study's planned enrollment of 240 is above the median of 194 across 531 interventional studies indexed under ST Elevation Myocardial Infarction.
Browse ST Elevation Myocardial Infarction studies →National Medical Research Center for Cardiology, Ministry of Health of Russian Federation is the lead sponsor of 20 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In-hospital thrombolysis with tenecteplase in case of predicted delayed pPCI (\>60 min after admission in PCI-center). Early tenecteplase, clopidogrel and enoxaparin followed by routine or rescue coronary intervention.
Drug: Single, weight-adjusted i.v. bolus of tenecteplase · Procedure: catheterisation
Standard primary PCI in case of predicted delayed pPCI (\>60 min after admission in PCI-center).
Procedure: catheterisation
Single, weight-adjusted i.v. bolus of tenecteplase in case of \>60 min in-hospital delay in PCI center
Standard primary PCI
Also known as: Routine or rescue coronary intervention
The number of observed patients with cardiovascular death, nonfatal stroke, and nonfatal AMI within 12 months for FAS.
Participants achieved a response if they have cardiovascular death or nonfatal stroke, or nonfatal AMI at 12 months.
Time frame: From enrollment to the end of follow-up (12 months).
Number of patients with all-cause mortality
Time frame: during hospitalization (assessed up to 10 days)
Number of patients with cardiovascular mortality
Time frame: during hospitalization (assessed up to 10 days)
Number of patients with non-fatal MI
Time frame: during hospitalization (assessed up to 10 days)
Number of patients with hemorrhagic stroke
Time frame: during hospitalization (assessed up to 10 days)
Number of patients with major bleeding according to the BARC scale (type 3-5)
Time frame: during hospitalization (assessed up to 10 days)
Number of patients with non-fatal complications of MI (AHF, cardiogenic shock, arrhythmias, MI, mechanical complications, thromboembolic complications )
Time frame: during hospitalization (assessed up to 10 days)
Number of patients with all-cause mortality
Time frame: 12 months
Number of patients with cardiovascular mortality
Time frame: 12 months
Number of patients with non-fatal MI
Time frame: 12 months
Number of patients with hemorrhagic stroke
Time frame: 12 months
Number of patients with major bleeding according to the BARC scale (type 3-5)
Time frame: 12 months
Number of patients with non-fatal complications of MI (AHF, cardiogenic shock, arrhythmias, MI, mechanical complications, thromboembolic complications)
Time frame: 12 months
Start is estimated for May 2026; primary completion for May 2028, 24 months later.
Of 44 non-industry phase 4 interventional studies under ST Elevation Myocardial Infarction, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 74. This study's planned 24 months is below that.
Counting every sponsor, half of 49 studies reached it within 34 months; a quarter within 22 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ST Elevation Myocardial Infarction →
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation